“The translation pathway from academic innovations to commercially viable patient outcomes is fundamentally broken. CASMI’s interdisciplinary mission is to readdress this unacceptable status quo. A mission that I am exhilarated by and committed to achieving.”
David Brindley, Research Fellow in Healthcare Translation
David is an international thought-leader in healthcare risk management, with a particular interest in regenerative medicines. His multi-disciplinary research seeks to evaluate and develop systematic, rigorous and transparent risk management tools supporting the translation of life-science innovations into commercially viable products and services.
In all cases, David strives to conduct research that is both academically rigorous and commercially practicable. His expertise spans the ‘Valley of Death,’ encompassing regulation, engineering and finance.
Regulation: Optimization of risk:benefit appraisal techniques for healthcare innovations
Engineering: Development of regenerative medicine biomanufacturing risk management tools
Clinical Engagement and Adoption: Provision of risk evaluation tools throughout the clinical development and delivery pathway
Finance: Identification and management of risks in the development pathway for healthcare innovations
Within CASMI, David leads all research activities pertaining to risk, and co-founded the CASMI Translational Stem Cell Consortium, with industrial lead Kim Bure (Sartorius Stedim). Examples of David’s impactful work can be found in a range of high impact journals including Nature, Nature Biotechnology, Nature Medicine and Cell Stem Cell. Additionally, David serves as an Editorial Board member for a range of international academic and industrial journals.
Keen to leverage novel media channels to access all stakeholders, David also produces a popular blog, Cell Therapy Industry 2027, with the Centre for the Commercialisation of Regenerative Medicine.
His work is made possible by the invaluable support of the Wellcome Trust, Technology Strategy Board, SENS Research Foundation, the New York Stem Cell Foundation, the NIH and a range of industrial and academic collaborators.
Outside the academia, David is an active Fellow of the Royal Institution of Great Britain and the Royal Society for the Advancement of Arts and Manufacturing. David has successfully passed the Charted Analyst in Alternative Investments (CAIA) Level 1 examination. David indulges his entrepreneurial spirit through his consultancy, Translation Ventures Ltd, providing timely and pragmatic advice and training to a range of stakeholders in healthcare translation, including the venture capital community. Additionally, David is a strategic advisor to a number of SMEs pursuing excellence in healthcare risk management solutions, including Spoonful of Sugar and Oxford Risk.
David completed his undergraduate studies in Biochemical Engineering at University College London with First Class Honors (Prof. Chris Mason and Dr Ivan Wall) and his Masters, investigating the commercialisation of regenerative therapies, jointly at the Harvard Stem Cell Institute (Mr Brock Reeve) and Harvard Business School (Prof. William Sahlman). Today, in addition to remaining an active member of the Harvard Stem Cell Institute and University College London (School of Pharmacy, Centre for Behavioral Medicine), David is pursuing a DPhil (PhD) in Musculoskeletal Sciences at the University of Oxford (Prof. Andrew Carr FMedSci and Prof. Sir John Bell FRS FMedSci), where he is a proud member of Worcester College.
Beyond life science translation, David is an aggressive tennis player, keen rower, passionate skier, aspiring sailor – and a lover of all things travel and epicurean! Additionally, in order to support student access to higher education, David recently completed a charity bike ride from Oxford to Venice.
The Global Intellectual Property Landscape of Induced Pluripotent Stem Cell Technology
Roberts, R.M., Wall, I.B., Bingham, I., Icely, D., Reeve, B., Bure, K., French, A. & Brindley, D.A. (2014) 32: 742–748
A Quantitative Assessment of Barriers to the Clinical Adoption of Cellular Therapies
Journal of Tissue Engineering (In Press)
Davies, B., Rikabi, S., French, A., Pinedo-Villanueva, R., Morrey, M.E.,Wartolowska, K., Judge, A., MacLaren, R.E., Mathur, A., Williams, D.J., Wall, I.B., Birchall, M., Reeve, B., Atala, A., Barker, R.W., Cui, Z., Furniss, D., Bure, K., Snyder, E.Y., Karp, J.M., Price, A., Carr, A.J.* & Brindley, D.A.*
*Joint senior author
Global Strategic Partnerships in Regenerative Medicine
Trends in Biotechnology
French, A., Suh, J.Y., Suh, C.Y., Rubin, L., Barker, R.W., Bure, K., Reeve, B. & Brindley, D.A. (2014), 32:9:436-440
Cell Therapy Biomanufacturing Risk Management
StemBook (August 2014 Edition)
Rehki, R., Wall, I., French, A., Bure, K., Carr, A.J. and Brindley, D.A (2014) “Cell Therapy Translation” edited by Williams, D. and Scadden, D.
An Evaluation of Regulatory and Commercial Barriers to Stratified Medicine Development and Adoption
Pharmacogenomics (September 2014 Edition)
Meadows, N., Morrison, A., Brindley, D.A., Schuh, A. & Barker, R.W.
Use of placebo control in the evaluation of surgery: a systematic review
British Medical Journal
Wartolowska, K., Judge, A., Hopewell, S., Collins, G.S., Dean, B.J.F., Rombach, Brindley, D.A., Savulescu,J., Beard, D.J. and Carr, A.J. (2014), 348:3253
Better drug access for terminal patients
Brindley, D.A., Barker, R.W. and Lachmann, P.J. (2013): Better drug access for terminal patients. Nature (502), 38
Good Genomic Practice (GGP): Essential for the Effective Use of Genomic Technologies to Support Improved Clinical Decision-Making
Barker, R.W., Brindley, D.A.* & Schuh, A. (2013) Good Genomic Practice (GPP): Essential for the Effective Use of Genomic Technologies to Support Improved Clinical Decision-Making. Nature Medicine, 19 (5), 530. *Joint first author
The Implementation of Novel Collaborative Structures for the Identification and Resolution of Barriers to Pluripotent Stem Cell Translation
Stem Cells and Development
Brindley, D.A., French, A., Suh, J., Roberts, M., Davies, B., Pinedo-Villanueva, R., Wartolowska, K., Rooke, K., Kramm, A., Judge, A., Morrey, M., Chandra, A., Hurley, H., Grover, L., Bingham, I., Siegel, B., Rattley, M.S., Buckler, R, McKeon, D., Krumholz, K., Hook, L., May, M., Rikabi, S., Pigott, R., Morys, M., Sabokbar, A., Titus, E., Laabi, Y., Lemaitre, G., Zahkia, R., Sipp, D., Horne, R., Bravery, C., Williams, D., Wall, I., Snyder, E.Y., Karp, J.M., Barker, R.W., Bure, K., Carr, A.J. and Reeve, B. (2013) The implementation of novel collaborative structures for the identification and resolution of barriers to pluripotent stem cell translation. Stem Cells and Development. 22(1S): 63-72
The Impact of Market Volatility on Cell Therapy Industry Growth
Cell Stem Cell
Brindley, D.A., Reeve, B.C., Sahlman, W.A., Davie, N.L., Culme-Seymour, E.J., Bonfiglio, G.A. & Mason, C. (2011) Cell Stem Cell 9: 397-401.
Pharmaceutical industry: Investors unfazed by drug-patent expiry
Brindley, D.A., Reeve, R & Mason, C. 2012 Pharmaceutical industry: Investors unfazed by drug-patent expiry. Nature 481, 265.
Promising growth and investment in the Cell Therapy Industry during the first quarter of 2012
Cell Stem Cell
Brindley, D.A., Reeve, B.C., Sahlman, W.A., Davie, N.L., Culme-Seymour, E.J., Bonfiglio, G.A. & Mason, C. (2012) Promising growth and investment in the Cell Therapy Industry during the first quarter of 2012. Cell Stem Cell, May 2012, Vol. 10(5), 492-496
Automation of Cell Therapy Biomanufacturing: Minimizing Regulatory Risks and Maximising Return on Investment
Brindley, D.A, Wall, I.B. & Bure, K. (2013) Automation of Cell Therapy Biomanufacturing: Minimizing Regulatory Risks and Maximising Return on Investment. Bioprocess International, Supplement; vol. 11, No. S3, March 2013, pp. 18–25.
Bioprocess Forces and Their Impact on Cell Behavior: Implications for Bone Regeneration Therapy
Journal of Tissue Engineering
Brindley, D., Moorthy, K, Lee, J., Mason, C., Kim, H. & Wall, I. (2011) Bioprocess Forces and Their Impact on Cell Behavior: Implications for Bone Regeneration Therapy. Journal of Tissue Engineering; vol. 2011, Article ID 62024
Cell therapy industry: billion dollar global business with unlimited potential
Mason, C., Brindley, D.A., Culme-Seymour, E.J. & Davie, N.L. (2011) Cell therapy industry: billion dollar global business with unlimited potential. Regenerative Medicine; 6: 265-272.
Human Embryonic Stem Cells in the Post Geron Era
Brindley, D.A. & Mason, C. (2012) Human Embryonic Stem Cells in the Post Geron Era. Regenerative Medicine 7(1) 17-18
Peak Serum: Implications for Cell Therapy Manufacturing
Brindley, D.A., Davie, N.L., Culme-Seymour, E.J., Mason, C., D.W. Smith & Rowley, J.A. (2012) Peak Serum: Implications for Cell Therapy Manufacturing. Regenerative Medicine 7(1), 7-13
A decade of cell therapy clinical trials (2000–2010)
Culme-Seymour E.J., Davie L.N., Brindley D.A., Edwards-Parton S. & Mason C. (2012). A decade of cell therapy clinical trials (2000–2010). Regenerative Medicine, July 2012, Vol. 7(4), 455-462
An Assessment of the Key Barriers to the Commercialization and Clinical Adoption of Pluripotent Stem Cell Therapies.
French, A., Bure, K. & Brindley, D.A. (2014) Rejuvenation Research 17(1):84-8
Streamlining Cell Therapy Manufacturing: From Clinical to Commercial Scale
Davie, N.D., Brindley, D.A.,* Culme-Seymour, E.J. & Mason, C (2012) Streamlining Cell Therapy Manufacturing: From Clinical to Commercial Scale. Bioprocess International, 10 (3), 24-29. *Joint first author.
Commercialization of Regenerative Medicine: Learning from Spin-Outs Rejuvenation Research
French, A., Buckler, R.L. & Brindley, D.A.* (2013) Commercialization of Regenerative Medicine: Learning from Spin-Outs. Rejuvenation Research: 16(2):164-70 *Senior Author
Regenerative medicine through a crisis: the social perception and the financial reality
Brindley, D. & Davie, N. (2009) Regenerative medicine through a crisis: the social perception and the financial reality. Rejuvenation Research; 12(6): 455-461
The Commercialisation of Cell Therapies
Brindley, D.A. & Mason, C. (2011) “The Commercialisation of Cell Therapies” featured in “Progenitor and stem cell technologies and therapies: Principles and Issues (Vol 1)” Woodhead Publishing, edited by Atala, A.
The Commercial Manufacture of Cell Therapies
Brindley, D.A. & Wall, I.B. (2012) “The Commercial Manufacture of Cell Therapies” featured in “Standardization in Cell and Tissue Engineering: Methods and Protocols,” Woodhead Publishing, edited by Salih, V.
Cell Therapy Manufacturing: Identifying and Meeting Demand
Brindley, D.A., Smith, D., Davie, N.L. and Carmen, J. (2013) “Cell Therapy Manufacturing: Identifying and Meeting Demand” featured in “The Commercial Translation of Cell Based Therapies” Springer, edited by Vertes, A.